Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down
NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and pipeline advances.
Open original sourceLoading market dashboard
NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and pipeline advances.
Open original source